Work

721 - Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study

Year: 2024

Type: article

Study design: Clinical Trial

Source: British Journal of Dermatology

DOI: 10.1093/bjd/ljae266.094

Authors: Amit G Pandya, Khaled Ezzedine, Thierry Passeron, Nanja van Geel, Kurt Brown, Leandro Santos, Lois Erskine, Kofi Wagya, Andrew Blauvelt

Institutions: Palo Alto Medical Foundation, The University of Texas Southwestern Medical Center, Université Paris-Est Créteil, Hôpitaux Universitaires Henri-Mondor, Inserm, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Centre Méditerranéen de Médecine Moléculaire, Ghent University Hospital, Incyte (United States), Oregon Medical Research Center

Language: English

Topic: melanin and skin pigmentation

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401436062

FWCI: 0.96

Cites:

Cited by: 6

Related to: 10